172733-79-8

Usage

Uses

Used in Pharmaceutical Industry:
Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one hydrochloride is used as a modulator for 11-β hydroxysteroid dehydrogenase type 1 (11-β HSD1) due to its ability to interact with and regulate the enzyme's activity. This modulation can have significant implications in the treatment of various metabolic disorders and diseases related to the dysregulation of steroid hormone metabolism.
Used in Drug Development:
In the field of drug development, Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one hydrochloride serves as a valuable compound for the design and synthesis of novel therapeutic agents targeting 11-β HSD1. Its unique structure and functional groups can be exploited to create new drugs with improved efficacy, selectivity, and safety profiles.
Used in Research and Development:
Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one hydrochloride is also utilized in research and development settings to study the role of 11-β HSD1 in various physiological and pathological processes. This can lead to a better understanding of the enzyme's function and the potential development of targeted therapies for related conditions.

Upstream product

• 54596-01-9 1'-benzylspiro[isobenzofuran-1(3H),4'-piperidin]-3-one hydrochloride 
• 37663-42-6 1'-benzylspiro[isobenzofuran-1(3H),4'-piperidine]-3-one 

Relevant academic research and scientific papers

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright

Efficient synthesis of a highly selective NPY-5 receptor antagonist: A drug candidate for the treatment of obesity

A concise and practical synthesis of highly selective NPY-5 receptor antagonist 1 is described. The animopyrazine intermediate 3 was synthesized via either monobromination of aminopyrazine or palladium-catalyzed regioselective debromination of dibromopyrazine followed by an efficient Suzuki-Miyaura coupling. For the preparation of the spirolactone piperidine 2, significantly improved yield was achieved by using a combination of n-BuMgCl and n-BuLi. This protocol also dramatically increased the thermal stability of the aryllithium intermediate and eliminated the requirement for costly cryogenic conditions. The union of the spirolactone piperidine 2 and aminopyrazine 3 via a carbonyl group was accomplished using phenyl chloroformate delivering the target molecule in high yield.

MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.